Risk factors
Cartesian Therapeutics (RNAC) risk factors
Item 1A of every Cartesian Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks4 new6 dropped8 reworded
Cartesian Therapeutics faces clinical and commercial uncertainties regarding its lead mRNA product candidate Descartes-08 for autoimmune disease. The company addresses financial runway, tax loss carryforward limitations, and intellectual property enforcement risks.
Filed Mar 09, 2026 - FY2024 10-K risk factors55 risks
Cartesian Therapeutics faces significant clinical-stage risks, heavy reliance on internal and third-party biological manufacturing, extensive IP and patent protection dependencies, and capital-raising needs to fund operations into mid-2027.
Filed Mar 13, 2025